Oxford, Moderna Eye July Phase 1 Trials for Ebola Bundibugyo Vaccine

Q: With millions funding three rival vaccines, which technology offers the fastest path to stopping this deadly Ebola outbreak?

The fastest near-term route appears to be Oxford’s ChAdOx1 viral-vector vaccine, while Moderna’s mRNA platform may be the fastest to scale if early data are strong. The reason ChAdOx1 leads on speed is timing. CEPI-backed reporting says the Oxford/Serum Institute candidate could reach Phase 1 readiness within roughly two to three months, making it the quickest of the three to get into people. In an active Ebola outbreak, that matters because ring-vaccination trials can begin only once doses and clinical-grade material are ready. Moderna’s mRNA candidate has a different advantage: manufacturing speed and flexibility. CEPI is backing not just preclinical work and Phase 1 testing, but also parallel manufacturing so larger trials can start quickly if the vaccine performs well. That makes mRNA the strongest option for compressing the path from design to mass production, a strength proven during COVID-19. But for Bundibugyo Ebola, it is still earlier in development than the Oxford shot. The IAVI rVSV candidate may offer the fastest protection after vaccination because this platform is associated with rapid immunity after a single dose, and its animal data are strong, including near-complete protection in monkeys. But it appears slower to reach trials, with estimates of seven months or more before clinical testing. So if the question is which technology can get into outbreak trials fastest, it is ChAdOx1. If the question is which could scale fastest once it works, it is mRNA.

3 articles · Updated · Reuters · Jun 16

July could bring Phase 1 trials for leading Ebola Bundibugyo vaccine candidates from Oxford University and Moderna, CEPI chief Richard Hatchett said on Tuesday.
Field trials could follow within several months if early testing advances, accelerating efforts against the strain spreading through eastern Democratic Republic of Congo.
The candidates target Ebola Bundibugyo, a deadly but less common Ebola virus, as health officials push to build tools quickly enough for outbreak use.

Sources

Reuters3d ago

Oxford, Moderna Ebola Bundibugyo Vaccines Eye July Phase 1 Trials

The Japan Times1d ago

The vaccines and treatments being developed for Ebola outbreak - The Japan Times

WIRED15h ago

The Most Promising Ebola Vaccine Has Been Sitting on the Shelf for 15 Years | WIRED

5 Sources

With millions funding three rival vaccines, which technology offers the fastest path to stopping this deadly Ebola outbreak?

After a vaccine was promised in 2024, why did it take a deadly outbreak two years later to restart development?

How can the world break its reactive cycle to known viral threats instead of scrambling for a cure each time?

2026 Bundibugyo Ebola Crisis: Rising Death Toll, Cross-Border Spread, and the Urgent Push for Vaccines

Overview

The Democratic Republic of the Congo (DRC) and Uganda are facing a serious resurgence of Bundibugyo virus disease (BVD), a form of Ebola, with sustained transmission and rapid geographic spread, especially in the DRC. As of mid-June 2026, the outbreak has led to 896 confirmed cases and 232 deaths in the DRC, showing a high case fatality rate. This escalating crisis demands immediate and coordinated international and local responses to prevent further spread. The situation highlights the urgent need for strong public health action and support to contain the outbreak and protect affected communities.

...